Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.

Abstract excerpt

PURPOSE OF REVIEW: Tumor protein 53 (TP53) protein is involved in fundamental processes of cancer, aging, and DNA repair. Thus, TP53 dysfunction is implicated in malignant processes and remains the most commonly mutated gene in cancer but represents a relatively small proportion in acute myeloid leukemia (AML). Patients with TP53-mutated AML attain inferior responses to therapy resulting in poor overall outcomes....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Induction Chemotherapy
• Share to Leukemia, Myeloid, Acute
• Share to Mutation